Aelis Farma today announced the publication of a series of studies on AEF0117, its first drug candidate dedicated to the treatment of disorders associated with excessive cannabis consumption (addiction and psychosis).

' This seminal article caps more than a decade of research, from the discovery of the natural mechanism used by the brain to oppose the effects of THC to our Phase 2a proof-of-concept clinical trial with AEF0117', said Dr Piazz, CEO of Aelis Farma.

In the Phase 2a trial, AEF0117 resulted in a statistically significant reduction in the subjective and reinforcing positive effects of cannabis, the laboratory points out.

According to Aelis, the results clearly suggest that AEF0117 could be an effective approach for patients seeking treatment for cannabis abuse disorders.

Aelis is now conducting a large Phase 2b placebo-controlled study, in collaboration with Columbia University Irving Medical Center, with 330 participants suffering from cannabis addiction, to evaluate three dose levels of AEF0117 in the treatment of cannabis addiction.

Results should be available by mid-2024.

Copyright (c) 2023 CercleFinance.com. All rights reserved.